---
title: "Fulcrum Therapeutics, Inc. (FULC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/FULC.US.md"
symbol: "FULC.US"
name: "Fulcrum Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-06-13T20:40:17.457Z"
locales:
  - [en](https://longbridge.com/en/quote/FULC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/FULC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/FULC.US.md)
---

# Fulcrum Therapeutics, Inc. (FULC.US)

## Company Overview

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.fulcrumtx.com](https://www.fulcrumtx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.02 | 145 | - | - | - |
| PB | 0.69 | 27 | 3.28 | 1.83 | 1.49 |
| PS (TTM) | 5.27 | - | 5.27 | 5.27 | 5.27 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-05T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 11% |
| Hold | 5 | 56% |
| Underweight | 3 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.45 |
| Highest Target | 25.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/FULC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/FULC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/FULC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/FULC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**